“We remain on track to report topline results in September from our Phase 2a trial of RAP-219 in patients with focal onset seizures,” said Abraham N. Ceesay, Chief Executive Officer of Rapport Therapeutics (RAPP). “This upcoming readout will be a pivotal milestone for our lead program and an opportunity to demonstrate the strength of our precision neuroscience approach. I’m also pleased to share that we have initiated our Phase 2 trial of RAP-219 in bipolar mania, and we are on track to report topline results in the first half of 2027. This is an important step forward as we advance RAP-219 into new areas of high unmet need and further build out our pipeline. Our team remains focused on executing these critical milestones and continuing to invest in our promising precision neuroscience discovery programs. We believe this disciplined approach positions us to deliver transformative treatments for patients and drive long-term value for our shareholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Buy Rating for Rapport Therapeutics, Inc. Driven by Promising Phase IIa Trial and RAP Technology Potential
- Buy Rating for Rapport Therapeutics: RAP-219’s Promising Potential in Epilepsy Treatment
- Rapport Therapeutics initiated with a Buy at H.C. Wainwright
- Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
- Rapport Therapeutics files to sell 470,589 shares of common stock for holders